Actavis launching its business in Ireland
With Actavis entering the Irish market last week, the plans are to create up to 25 new local jobs over the next five years and to launch over 120 generic drugs in Ireland, with the potential to save millions of euro off the country’s annual health bill.
The new roles Actavis will create are in addition to 11 corporate employees currently based in Ireland.
Managing Director of Actavis Ireland, Tony Hynds, said:
“Over the next five years, we plan to rapidly expand our offering in Ireland in all channels - hospital-specific, prescription and over the counter medicines.”
Hynds said the arrival of Actavis into the Irish market came at a time when the country was struggling to meet the rapidly rising cost of healthcare.
“In Ireland, Actavis has established a team with deep expertise in the local industry, people who understand the nature of the market here, and has given them the backing of a vast global product pipeline,” Hynds added.
Actavis launched a generic cancer treatment drug, Gemcitabine, on the Irish market last Monday. It was made available for prescription from 9th March, on day one when the patent for Gemcitabine expired in Ireland.
- Contact Information
- Hjordis Arnadottir
- Director, External Communications
- Actavis Group
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.